These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

369 related items for PubMed ID: 31346821

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. More advantages in detecting bone and soft tissue metastases from prostate cancer using 18F-PSMA PET/CT.
    Pianou NK, Stavrou PZ, Vlontzou E, Rondogianni P, Exarhos DN, Datseris IE.
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Clinical Translation and First In-Human Use of [44Sc]Sc-PSMA-617 for PET Imaging of Metastasized Castrate-Resistant Prostate Cancer.
    Eppard E, de la Fuente A, Benešová M, Khawar A, Bundschuh RA, Gärtner FC, Kreppel B, Kopka K, Essler M, Rösch F.
    Theranostics; 2017; 7(18):4359-4369. PubMed ID: 29158832
    [Abstract] [Full Text] [Related]

  • 6. Radiation dosimetry of [68Ga]PSMA-11 in low-risk prostate cancer patients.
    Sandgren K, Johansson L, Axelsson J, Jonsson J, Ögren M, Ögren M, Andersson M, Strandberg S, Nyholm T, Riklund K, Widmark A.
    EJNMMI Phys; 2019 Jan 11; 6(1):2. PubMed ID: 30631980
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. [68Ga]Ga-P16-093 as a PSMA-Targeted PET Radiopharmaceutical for Detection of Cancer: Initial Evaluation and Comparison with [68Ga]Ga-PSMA-11 in Prostate Cancer Patients Presenting with Biochemical Recurrence.
    Green MA, Hutchins GD, Bahler CD, Tann M, Mathias CJ, Territo W, Sims J, Polson H, Alexoff D, Eckelman WC, Kung HF, Fletcher JW.
    Mol Imaging Biol; 2020 Jun 11; 22(3):752-763. PubMed ID: 31429050
    [Abstract] [Full Text] [Related]

  • 10. An 89Zr-Labeled PSMA Tracer for PET/CT Imaging of Prostate Cancer Patients.
    Dietlein F, Kobe C, Vázquez SM, Fischer T, Endepols H, Hohberg M, Reifegerst M, Neumaier B, Schomäcker K, Drzezga AE, Dietlein M.
    J Nucl Med; 2022 Apr 11; 63(4):573-583. PubMed ID: 34326129
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Biodistribution and radiation dosimetry of (68)Ga-PSMA HBED CC-a PSMA specific probe for PET imaging of prostate cancer.
    Pfob CH, Ziegler S, Graner FP, Köhner M, Schachoff S, Blechert B, Wester HJ, Scheidhauer K, Schwaiger M, Maurer T, Eiber M.
    Eur J Nucl Med Mol Imaging; 2016 Oct 11; 43(11):1962-70. PubMed ID: 27207281
    [Abstract] [Full Text] [Related]

  • 13. Pre-therapeutic dosimetry of normal organs and tissues of (177)Lu-PSMA-617 prostate-specific membrane antigen (PSMA) inhibitor in patients with castration-resistant prostate cancer.
    Kabasakal L, AbuQbeitah M, Aygün A, Yeyin N, Ocak M, Demirci E, Toklu T.
    Eur J Nucl Med Mol Imaging; 2015 Dec 11; 42(13):1976-83. PubMed ID: 26227531
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Radiation dosimetry of (68)Ga-PSMA-11 (HBED-CC) and preliminary evaluation of optimal imaging timing.
    Afshar-Oromieh A, Hetzheim H, Kübler W, Kratochwil C, Giesel FL, Hope TA, Eder M, Eisenhut M, Kopka K, Haberkorn U.
    Eur J Nucl Med Mol Imaging; 2016 Aug 11; 43(9):1611-20. PubMed ID: 27260521
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Preclinical Evaluation and Pilot Clinical Study of Al18F-PSMA-BCH for Prostate Cancer PET Imaging.
    Liu T, Liu C, Xu X, Liu F, Guo X, Li N, Wang X, Yang J, Yang X, Zhu H, Yang Z.
    J Nucl Med; 2019 Sep 11; 60(9):1284-1292. PubMed ID: 30796170
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. [18F]AlF-NOTA-octreotide PET imaging: biodistribution, dosimetry and first comparison with [68Ga]Ga-DOTATATE in neuroendocrine tumour patients.
    Pauwels E, Cleeren F, Tshibangu T, Koole M, Serdons K, Dekervel J, Van Cutsem E, Verslype C, Van Laere K, Bormans G, Deroose CM.
    Eur J Nucl Med Mol Imaging; 2020 Dec 11; 47(13):3033-3046. PubMed ID: 32617641
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.